ALK and non-small cell lung carcinoma: Certain rare mutations in NSCLC, such as different subtypes of ALK fusion, having a prone for treatment resistance, leading to higher recurrence rate and poor prognosis.[8,9] NGS possessed ability to detect and identify rare mutation variants through high-throughput and deep sequencing.[10]